Skip to content

A Multicenter Clinical Study on the Effects of Combined Neuromodulation and VR Balance Training on Post-Stroke Balance and Gait Function

A Multicenter Clinical Study on the Effects of Combined Neuromodulation and VR Balance Training on Post-Stroke Balance and Gait Function

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2500113419
Enrollment
Unknown
Registered
2025-11-27
Start date
2026-01-01
Completion date
Unknown
Last updated
2026-06-08

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Stroke

Interventions

VR Balance + tDCS Group:Provide conventional rehabilitation therapy, supplemented by VR balance training and tDCS treatment.
Sham VR Balance + Sham tDCS Group:Provide conventional rehabilitation therapy, supplemented by sham VR balance training and sham tDCS treatment.
VR Balance + Sham tDCS Group:Provide conventional rehabilitation therapy,supplemented by VR balance training and sham tDCS treatment.
Sham VR Balance + tDCS Group:Provide conventional rehabilitation therapy, supplemented by sham VR balance training and tDCS treatment.

Sponsors

Tongji Hospital, Tongji Medical College of Huazhong University of Science and Technology
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 75 Years

Inclusion criteria

Inclusion criteria: 1. Meets the diagnostic criteria for stroke in the "Key Points for the Diagnosis of Major Cerebrovascular Diseases in China (2019)" and is confirmed by head CT or MRI imaging as a first-ever unilateral stroke; 2. Disease course > 2 weeks and 18 years and = 21 points; 6. No unilateral neglect (Albert's test); 7. Berg Balance Scale score >= 20 points and <= 51 points; 8. Able to walk independently using a walker for at least 10 meters; 9. Informed consent provided and voluntarily participating in this study.

Exclusion criteria

Exclusion criteria: 1.Patients with other neurological conditions (e.g., multiple sclerosis, Parkinson's disease) or severe medical comorbidities (e.g., cardiac, renal, or respiratory failure; active malignancy) beyond the initial stroke; 2.Patients with cerebellar or brainstem strokes; severe visual, hearing impairments, or psychiatric disorders; 3.Spinal instability or unstable fractures; 4.History of epileptic seizures or current use of medications that may alter cortical excitability (e.g., antiepileptic drugs, benzodiazepines, etc.); 5.Previous brain surgery or intracranial metal implants; 6.Pregnant or lactating women; 7.Inability to comply with study procedures or sign the informed consent form.

Design outcomes

Primary

MeasureTime frame
Berg Balance (BBS);Timed Up and Go (TUGT);

Secondary

MeasureTime frame
FMA-Lower Extremity Motor Function;10 Meter Walk (10WMT);Modified Barthel Index (MBI);Montreal Cognitive (MoCA) ;Hamilton Anxiety (HAMA);Hamilton Depression(HAMD);Falls Efficacy-International (FES-I);Activity-specific Balance Confidence(ABC);Stroke Specific Quality of Life (SS-QOL);Gait ;Electromyogram(EMG) and Evoked potential(EP);Electroencephalogram(EEG);Changes in brain activation intensity, functional connectivity, and brain network topological properties before and after intervention;Dynamic changes in oxyhemoglobin and deoxyhemoglobin concentrations;

Countries

China

Contacts

Public ContactYali Liu

Tongji Hospital, Tongji Medical College of Huazhong University of Science and Technology

liuyali74@126.com+86 138 8617 1269

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Jun 11, 2026